Earnings Release • May 10, 2022
Earnings Release
Open in ViewerOpens in native device viewer
va-Q-tec Q1 2022 Earnings Release Presentation
10th May 2022
Revenue up +25 % in Q1 2022 to EUR 28,0 million compared to EUR 22,4 million in Q1 2021
+
+
+
+
Outstanding growth in the Services (+48 %) and Systems (+29 %) divisions
EBITDA in Q1 2022 of EUR 3,9 million compared to EUR 4,6 million in Q1 2021 (-16 %); EBITDA margin of 13 % in Q1 2022 compared to 16 % in Q1 2021 based on total income
Significantly improved operating cash flow and capex reduction; free cash flow in Q1 2022 up by around EUR 3,7 million year-on-year and positive
3
| Q1 22 In Mio. EUR |
Q1 21 In Mio. EUR |
Difference in % |
||
|---|---|---|---|---|
| Revenue | 27.988 | 22.359 | +25% | |
| Total income | 30.940 | 28.445 | +9% | |
| Cost of Materials and Services | -12.261 | -12.400 | - | |
| Gross profit | 18.679 | 16.045 | +16% | |
| Personnel expenses | -9.273 | -7.811 | +19% | Anticipated future business |
| Other operating expense | -5.541 | -3.646 | +52% | Higher logistics and energy costs, |
| EBITDA | 3.865 | 4.588 | -16% | travel costs |
| Depreciation & amortization | -3.729 | -3.163 | +18% | |
| EBIT | 136 | 1.425 | ||
| Financial result | -621 | -528 | ||
| EBT | -485 | 897 | ||
| Income taxes | -442 | 156 | ||
| Net income (EAT) | -927 | 1.053 |
| In Mio. EUR | Q1 22 | Q1 21 | Comments | |
|---|---|---|---|---|
| Operating cash flow before changes in Working Capital |
3,6 | 4,6 | • Operating CF with a strong development, +62% yoy |
|
| Operating cash flow | 2,1 | 1,3 | term growth mainly done | |
| Investing cash flow | -2,1 | -4,9 | ||
| Thereof payments for investments in property, plant and equipment* |
-2,1 | -5,0 | • Positive FCF, +3,7 Mio. EUR improvement |
|
| Financing cash flow | 0,2 | -2,1 | ||
| Net change in cash | 0,2 | -5,8 | 2022 | |
| Free cash flow | 0,04 | -3,6 | ||
| Cash and cash equivalents | 10,1 | 11,4 | Available lines + cash = |
*c. 80% growth CAPEX
15,8 Mio. EUR
Solid equity ratio of 35%, no goodwill No Goodwill, Net Debt excl. mortgage loans: 2.0x last 12 months EBITDA
Short-term outlook
| Guidance FY22e | Assumptions | |
|---|---|---|
| Revenues | 115-122 Mio. EUR | • With ~75% Healthcare revenues in 2022E, stable business assumed • No major negative impact from geopolitical tensions • Supply chain constraints and increased inflation considered to some extent |
| EBITDA | Growing – stable Margins |
70% of the world's top-selling pharmaceuticals require strictly temperature-controlled supply chain [TempChain].
Alfred-Nobel-Straße 33 97080 Würzburg Tel,: +49 931 35942-1616 Fax: +49 931 35942-0 IR@va-Q-tec,com
Symbol: VQT Bloomberg: VQT:GY Reuters: VQTG:DE ISIN: DE0006636681 WKN: 663668
11
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.